Neuroblastoma is a pediatric tumor that originates from precursor cells of the sympathetic nervous system with less than 40% longterm survival in children diagnosed with high-risk disease. These clinical observations underscore the need for novel insights in the mechanisms of malignant transformation and progression. Accordingly, it was recently reported that Prox1, a homeobox transcription regulator, is expressed in higher levels in human neuroblastoma with favorable prognosis. Consistently, we have recently shown that Prox1 exerts a strong antiproliferative effect on neural precursor cells during embryonic development. Thus, Prox1 is a candidate gene with a critical role in suppressing malignant neuroblastoma transformation. Here, we provide evidence that Prox1 strongly suppresses the proliferation of mouse and human neuroblastoma cell lines and blocks the growth of neuroblastoma tumors in SCID mice. Conversely, short hairpin RNA (shRNA) -mediated knockdown of basal Prox1 expression significantly induces proliferation, genomic instability and the ability of neuroblastoma cells to form tumors. Mechanistically, analysis of an inducible Prox1-overexpressing Neuro2A cell line indicates that Prox1 is sufficient to suppress CyclinD1, CyclinA and CyclinB1, consistent with a role in cell cycle arrest. Surprisingly, Prox1 strongly induces CyclinE1 expression in the same system despite its action on blocking cell cycle progression, which could account for the context dependent oncogenic function of Prox1. Most importantly, Prox1 was sufficient to decrease Cdc25A and induce p27-Kip1, but not p21-Cip1 or p53. By alleviating the Prox1 action in Cdc25A and p27-Kip1 expression, we were able to rescue its effect on cell cycle arrest. Together these data suggest that Prox1 negatively regulates neuroblastoma carcinogenesis through suppression of Cdc25A and induction of p27-Kip1 to counteract CyclinE1 overexpression and block cell cycle progression. Furthermore, these observations render Prox1 a candidate target for the treatment of neuroblastoma tumors.
INTRODUCTION
Neuroblastoma is a malignancy of early childhood that arises from the developing autonomic nervous system. 1 The clinical behavior is variable, ranging from spontaneous regression to highly aggressive metastatic disease with a poor overall survival rate. It is the most frequently diagnosed neoplasm during infancy and less than 40% of children with high-risk neuroblastoma are likely to achieve long-term cure, despite dramatic escalations in the intensity of therapy provided. 2 Future therapies will focus increasingly on the genes and biological pathways that contribute to this malignancy.
Towards this aim, it was recently reported that expression of Prox1, a homeobox transcription regulator, in human neuroblastoma tumors is correlated with the stage 4S, which has favorable prognosis with high incidence of spontaneous regression. Moreover, it was shown that Prox1 is highly expressed in sympathetic neurons during early stages of development in chick, mouse and human peripheral nervous system and its expression levels are reduced in highly proliferative human neuroblastoma cell lines. 3, 4 These observations suggest that Prox1 might have a tumor suppressor function in neuroblastoma cancer. Accordingly, we have recently reported that Prox1 negatively regulates the proliferation of neural precursor cells during embryonic development. Furthermore, we showed that a cross-inhibitory interaction between Prox1 and Notch1 is involved in the regulation of proliferation and differentiation in neural precursor cells. 5 In agreement, recent data suggest that Notch1 expression predicts an unfavorable prognosis for patients with neuroblastoma and could serve as a therapeutic target. 6 Therefore, Prox1 may be involved in the malignant transformation, progression and/or regression of neuroblastoma through Notch signaling regulation and/or additional genes and pathways.
Multiple lines of evidence suggest important roles for Prox1 in different aspects of embryonic development and morphogenesis, while mouse embryos deficient in Prox1 die at E14.5. Prox1 has been previously shown to have essential roles during lymphatic, hepatocyte, pancreatic, heart, lens, retinal and spinal cord development. 5, [7] [8] [9] [10] Prox1 has also been implicated in both progression and suppression of malignancies. A function for Prox1 as tumor suppressor has been described previously in other systems. Decreased expression levels have been found in hepatocellular and pancreatic carcinoma, 11, 12 which may be due to epigenetic silencing. Hypermethylation of the Prox1 gene has been found in breast cancer and lymphomas and in brain metastases of breast cancer. 13, 14 Moreover, mutations of Prox1 and loss of heterozygosity have been reported in various cancers. 13, 15, 16 Although most studies point to a tumor suppressor function of Prox1, a recent study reports that it enhances colorectal cancer progression. 17 These data suggest that Prox1 may function in a context dependent manner, being a tumor suppressor in certain cells, while in other cell types could be related to tumor progression. This dual function may reside in the fact that Prox1 affects differentially the expression of genes that promote or inhibit proliferation and cell cycle progression.
Here, we provide functional evidence that Prox1 is indeed involved in the suppression of neuroblastoma cell growth both in vitro and in vivo. Mechanistically, activated Notch1 signaling cannot rescue the negative effect of Prox1 on neuroblastoma proliferation, suggesting an alternative mode of action. Accordingly, we showed that Prox1 acts in basic components of cell cycle machinery to regulate cellular proliferation in neuroblastoma cells. Collectively, these observations indicate that Prox1 negatively regulates tumorigenic properties of neuroblastoma cells, may be implicated in suppressing neuroblastoma carcinogenesis, and could be utilized for its treatment.
RESULTS

Prox1 blocks proliferation of neuroblastoma cancer cells
To evaluate whether the observed correlation between Prox1 expression and suppression of neuroblastoma progression has functional importance, we used neuroblastoma cell lines as a model system to analyze proliferation. We first examined the effect of mouse or human Prox1 overexpression in Neuro2A (N2A) mouse neuroblastoma cell line. BrdU incorporation assays revealed a strong block in proliferation after mouse or human Prox1 overexpression (Figures 1a and b and Supplementary Figure  S1a) . In addition, immunostainings with phosphorylated-histoneH3 (pH3) revealed a strong reduction in Prox1 þ N2A cells undergoing mitosis (Figures 1d and e and Supplementary Figure  S1b) . To exclude the possibility of non-cell autonomous effects, we also measured the proliferation rate in the nontransfected cells. In all cases, the untransfected cells in Prox1 experiments showed proliferation rates similar to green fluorescent protein (GFP) experiments (Figures 1c and f) , further confirming that the defect in proliferation is because of Prox1 overexpression. Prox1 was also sufficient to suppress proliferation in human neuroblastoma cell lines, including SH-SY5Y and Kelly (Figures 1g and h ). We next asked whether the lower proliferative rate of Prox1 transfected cells is owing to cell death. No evidence of induction of apoptosis was observed in Prox1 transfected cells compared with GFP or RFP as documented by TUNEL assay and PE/AnnexinV fluorescenceactivated cell sorting analysis (FACS) (Figure 2 ). To further validate the Prox1-mediated impairment of cell proliferation, we transfected N2A cells with either GFP or Prox1-GFP and we then analyzed the clonal formation of fluorescent cells (Supplementary Figure S2) . Although GFP þ clones tend to form large colonies with many cells few days after plating, Prox1-GFP þ clones stayed single cells. Most of them stayed quiescent without dying for at least 7 days after plating (Supplementary Figure S2 and data not shown), whereas untransfected cells in the same well formed large colonies (that is, Supplementary Figure S2a , Day4, phase contrast).
To further study the involvement of Prox1 in neuroblastoma cell growth both in vitro and in vivo, we constructed a set of inducible Tet-On N2A stable cell lines capable to efficiently induce Prox1 or GFP expression (Figures 3a and b) . First, we confirmed that Prox1 induction after doxycycline (Dox) administration strongly inhibits proliferation of these cells (Prox1-Tet) as compared with noninduced or GFP-induced (GFP-Tet) cells (Figures 3c-j) , with no induction of apoptosis (data not shown). We verified these observations with MTT assay and PCNA immunostainings (Figures  3k-m) . Collectively, these observations show that Prox1 negatively affects proliferative and tumor forming abilities of neuroblastoma cells in vitro with no indication of increased cell death.
shRNA-mediated knockdown of Prox1 enhances proliferation of neuroblastoma cells To test whether the low, basal expression levels of Prox1 in neuroblastoma cell lines 3 are involved in regulating proliferation of these cells, we constructed a set of stable cell lines, expressing different shRNAs targeting the mouse Prox1 homolog. To this end, we utilized five different shRNAs constructs for Prox1 and one control scrambled construct based on the lentiviral TRC library (Sigma, St Louis, MO, USA). In particular, we infected WT N2A cells with the indicated lentiviruses and subjected the infected cells in puromycin selection to construct six distinct stable cell lines. One of them, designated shRNA-55 (hereafter referred as shProx1), was capable to strongly downregulate the endogenous Prox1 mRNA levels ( Figure 4a ). We further confirmed the ability of this vector to downregulate Prox1 expression by constructing a set of stable cell lines based on Prox1-Tet, able to induce Prox1 and stably express this shRNA as indicated in Figure 4b . Thus, shProx1 was sufficient to block the Dox-mediated induction of Prox1 in the Prox1-Tet cell background, as compared with the scrambled or another shRNA vector (shRNA-57) (Figures 4c and d) . Remarkably, the shProx1 stable cell line, with much reduced levels of endogenous Prox1 (Figure 4a ), showed significantly enhanced proliferative rates as compared with shSCR (shScramble) control cell line (Figures 4e-h ). In agreement, this cell line exhibited increased levels of genomic instability, manifested by higher percentage of cells with large nuclei (Figures 4i and j) , indicative of aberrant control of proliferation. To exclude off-target effects and assess the specificity of Prox1-shRNA phenotypes, we repeated the same set of experiments with the shRNA-56 cell line (Supplementary Figure S3 ). This cell line showed enhanced proliferative capacity similar to shRNA-55, further confirming the effect of Prox1 knockdown on proliferation and genomic instability. Together these data suggest that Prox1 is sufficient and necessary for the proper regulation of proliferation in neuroblastoma cells.
Prox1 strongly suppresses neuroblastoma tumor growth in vivo
To examine whether the Prox1-mediated inhibition of cell proliferation is recapitulated under more physiological conditions, Prox1-Tet and GFP-Tet clones were transplanted subcutaneous in SCID mice. We transplanted Prox1-Tet (right side) and GFP-Tet (left side) clones as pairs in the same animals, as indicated in Figure 5a Figure S4) , whereas cells that escaped Prox1 induction had pH3 þ index similar to that of the GFP þ cells in GFP-Tet tumors (Figure 5j and data not shown). Thus, as was the case in vitro, the reduced N2A tumor growth rate was owing to reduced cell proliferation. Conversely, a significant increase was observed in the volume of shProx1 tumors, compared with the control shSCR tumors, as early as 14 days after transplantation of both cell lines (Figures 5l and m) . Taken together, our results demonstrate that Prox1 suppresses the oncogenic properties of neuroblastoma cells in vivo.
The Prox1 effect on neuroblastoma proliferation is independent of its action on Notch signaling We have previously shown that Prox1 inhibits Notch1 expression at the transcriptional level. 5 Notch signaling has a critical role in neuroblastoma pathogenesis, particularly related to its key function in neural development. 18 Activated Notch1 signaling inhibits neuronal differentiation and maintains precursors of the autonomic and central nervous system in a proliferative state. These data raised the possibility that Prox1 may act through Notch1 signaling inhibition to achieve its antiproliferative action. Thus, co-expression of constitutively active form of Notch1 (NICD) was not sufficient to rescue the antiproliferative effect of Prox1 on neuroblastoma cells (Figures 6a-e) . These results suggest that Prox1 induces cell cycle exit through the regulation of additional genes and/or pathways other than Notch1. Moreover, we have previously shown that pharmacological inhibition of Notch signaling induces the expression of Prox1 in neural precursor cells. 5 However, in neuroblastoma cells even high doses of DAPT inhibitor cannot induce the expression of endogenous Prox1 (Supplementary Figure S5) . Accordingly, DAPT-mediated inhibition of Notch signaling was able to only partially affect proliferation of N2A cells (Figure 6f and data not shown), consistent with the inability of DAPT inhibitor to induce Prox1. Therefore, the mild effect of Notch inhibition on N2A proliferation is also independent of Prox1 function.
Prox1 blocks cell cycle progression in G0/G1 phase To further investigate the mechanism of Prox1 action, we analyzed the cell cycle properties of Prox1-Tet cells after Dox induction. FACS analysis carried out 48 h after Dox induction indicated a cell cycle exit in G0/arrest in G1 phase as compared with the GFP-Tet cells (Figures 7a and b) , consistent with the observations that Prox1-Tet do not enter S phase and do not accumulate around mitosis, as shown by BrdU and pH3 assays, respectively (Figures  3c-j) . In agreement, Prox1 induction was sufficient to reduce the levels of CyclinA, CyclinB1 and CyclinD1 (Figure 7c and Supplementary Figure S6) . Especially for the G1-specific CyclinD1, we confirmed this finding by measuring the index of cells that coexpress CyclinD1 and Prox1 or GFP in Prox1-Tet versus GFP-Tet cells, respectively (Figures 7e and f) . Moreover, Prox1 affects CyclinD1 in a similar manner in human neuroblastoma SH-SY5Y cells (Supplementary Figures S7a and S7b) . Strikingly, despite the effect on cell cycle arrest, Prox1 was also able to enhance the expression of CyclinE1 (Figures 7c,d,g and h) . In these cultures, endogenous CyclinE1 is upregulated upon induction of Prox1 at the protein level (Figures 7c and d) and a concomitant induction in the number of CyclinE1 þ cells is also observed in N2A cells (Figures 7g and h) , as well as in human SH-SY5Y cells (Supplementary Figure S7c-7f ). Similar to previous reports, 20 the Prox1-mediated induction of CyclinE1 was at the transcription level (Figures 7i and j) . To further confirm that Prox1 differentially affects the expression of G1 Cyclins, we analyzed the expression of CyclinD1 and E1 in sections from Prox1-Tet and GFP-Tet tumors. Similar to the in vitro data, immunohistochemical analysis in tumors indicates that Prox1 suppresses the expression of CyclinD1 and induces the expression of CyclinE1 (Figures 7k-n) .
We then asked whether Prox1 affects the expression of cdk inhibitors that act in G1 phase. To this end, we performed western blot analysis for p27-Kip1 and p21-Cip1. Interestingly, Prox1 was sufficient to induce p27-Kip1 but not p21-Cip1 or its upstream activator p53 (Figures 8a,b and d) . Moreover, we confirmed the Prox1 effect on p27-Kip1 expression in human SH-SY5Y cells ( Supplementary Figures S8a and b) . To determine whether Prox1 affects the expression of p27-Kip1 at the transcriptional level, we measured the p27-Kip1 mRNA levels in Prox1-Tet and GFP-Tet cells. The Prox1-Tet cells showed significantly enhanced mRNA levels of p27-Kip1, indicative of an action at the level of transcriptional regulation (Figure 8e ).
In addition, given that Prospero, the Drosophila homolog of Prox1, suppresses the expression of Drosophila homologue for Cdc25A (String), 21, 22 we sought to test whether Prox1 also affects Cdc25A expression in neuroblastoma cells. Accordingly, a concomitant reduction in expression of the Cdc25A phosphatase was also evident after Prox1 expression in our inducible N2A cell Prox1 blocks cell cycle progression in neuroblastoma cells IP Foskolou et al line (Figures 8a and c) , as well as in SH-SY5Y cells (Supplementary Figure S8c-f ). Similar to p27-Kip1, real time RT-PCR and transcriptional assays in N2A cells suggest that Prox1 is sufficient to repress Cdc25A expression at the transcriptional level ( Figures  8f and g ). Considering that the activity of Cdc25A is required in mammalian cells for S phase progression, 23 it could be one of the putative targets of Prox1 antiproliferative function.
To further investigate whether the Prox1-mediated regulation of p27-Kip1 (encoded by Cdkn1b gene) and Cdc25A is direct, we performed chromatin immunoprecipitation experiments. In particular, by using a series of PCR primer pairs we screened the corresponding gene promoters for Prox1-binding events (Figures  9a and c) . Thus, we were able to identify genomic loci close to the transcription start sites of Cdkn1b and Cdc25A genes that were specifically enriched in our chromatin immunoprecipitation assays for Prox1-Tet cells compared with GFP-Tet cells or compared with other loci in the same genomic region (Figures 9b and d) . These data suggest that Prox1-mediated transcriptional regulation of Cdkn1b and Cdc25A genes may be through direct interactions with their promoters.
Taken together these observations suggest that Prox1 may act on proliferation of neuroblastoma cells through a combined effect on various components of the cell cycle control machinery, including Cyclins, p27-Kip1 and Cdc25A.
Cdc25A overexpression and p27-Kip1 knockdown rescue the antiproliferative effect of Prox1 To assess whether the observed correlations between Prox1 and the components of cell cycle control machinery have functional importance, we performed a series of overexpression and knockdown experiments in N2A cells in an attempt to recapitulate or rescue the Prox1-mediated effect on cell proliferation. We first examined the effect of CyclinE1 overexpression on N2A cell proliferation (Supplementary Figure S9a) . BrdU incorporation analysis and pH3 immunostainings 48 h after transfection revealed a significant induction in proliferation (Supplementary Figures S9b  and e) . Therefore, both indices show that CyclinE1 overexpression induces the proliferation of N2A cells, in clear contrast to Prox1 misexpression, indicating that CyclinE1 cannot recapitulate the Prox1 effect on growth of neuroblastoma cells.
We next asked whether the Prox1-mediated suppression of Cdc25A could explain its strong antiproliferative action. To this end, we co-expressed Cdc25A 24 together with Prox1 (Supplementary Figure S10) and measured proliferation by BrdU and pH3 48 h after transfection (Figures 10a-d) . Interestingly, Cdc25A co-expression was able to partially rescue the effect of Prox1, by 32.1 and 33.3%, respectively. These observations suggest that the Prox1-mediated downregulation of Cdc25A is significantly involved in the antiproliferative function of Prox1.
However, additional mechanisms should operate, as Cdc25A confers only a partial rescue of the Prox1 effect.
Accordingly, we then tested whether the ability of Prox1 to induce p27-Kip1 is also involved in this function. First, p27-kip1 overexpression was sufficient to recapitulate the Prox1 effect on cell proliferation (Supplementary Figure S11) . Second, to further examine this scenario, we utilized a previously tested shRNA construct that targets and efficiently downregulates the mouse homolog for p27-Kip1 (confirmed in Supplementary Figure S12) . 25 We then transiently transfected N2A cells with the indicated constructs and employed BrdU incorporation and pH3 assays to measure proliferation (Figures 10e-h) . Hence, shRNA-mediated knockdown of endogenous p27-Kip1 in N2A cells can significantly rescue the negative effect of Prox1 on cell proliferation, by 48.36 and 58.87%, respectively. To further confirm these observations, we transfected the Prox1-Tet and GFP-Tet cells with the shRNA construct for p27-Kip1. Similar to the transiently transfected N2A cells, shRNA-mediated knockdown of p27-Kip1 in the Prox1-Tet cells was again sufficient to partially rescue Prox1 effect on proliferation (Supplementary Figure S13) . Next, to test whether simultaneous misexpression of Cdc25A and ablation of p27-Kip1 can fully rescue the Prox1 effect, we did triple transfection experiments with the shRNA for p27-Kip1, Cdc25A and Prox1 expression vectors. Interestingly, by simultaneously alleviating the action of Prox1 on the expression levels of Cdc25A and p27-Kip1, we were able to almost fully rescue the Prox1-mediated impairment of cell proliferation (Figures 10i-l) .
Finally, by using a series of deletion mutants for the Prox1 protein in proliferation assays, we showed that various domains are differentially required for mediating its antiproliferative effect (Supplementary Figure S14) . Almost all domains showed some degree of rescue ability, in agreement with a combinatorial action of Prox1 in various components of the cell cycle regulatory machinery. In all cases, deletion of the DNA binding domain from the carboxy terminal of Prox1 protein was sufficient to fully rescue the antiproliferative effect, consistent with the observation that Prox1 action on Cdc25A and p27-Kip1 occurs primarily at the transcriptional level.
Taken together these observations indicate that Prox1 negatively regulates neuroblastoma carcinogenesis through its ability to suppress Cdc25A and induce p27-Kip1 to counteract CyclinE1 overexpression and block cell cycle progression (Figure 10m) . Furthermore, these observations render Prox1 a candidate target for the treatment of neuroblastoma tumors.
DISCUSSION
Recent data suggest that Prox1 transcription regulator is involved in the early events of neuroblastoma carcinogenesis, thus being potential target for cancer therapy. 3, 4, 26 These correlative data raised the possibility that Prox1 may act as a tumor suppressor gene in neuroblastoma cancer. Accordingly, in this study, we show that Prox1 strongly inhibits the ability of neuroblastoma cells to proliferate, whereas endogenous expression levels are necessary for the proper regulation of cell proliferation both in vitro and in vivo. Prox1 blocks neuroblastoma cell cycle in G0/G1 phase, being able to downregulate CyclinD1, CyclinA and CyclinB1. In agreement, it has been previously reported that Prox1 is sufficient to suppress proliferation in various cell lines or primary cells from other tissues, including hematopoetic stem/progenitor cells, 27, 28 neural precursor cells, 5, 29, 30 HEK293, pancreatic cell lines (that is, miapaca2), 16 Hep3B and Huh7cells, 12 and KYSE esophageal cancer cell line. 31 Consistently, decreased expression levels, silencing and/ or loss-of-function mutations for Prox1 have been found in various cancers, including hematological malignacies, hepatocellular, bilary duct, pancreatic and breast cancers. [11] [12] [13] [14] [15] [16] 32 However, the detailed molecular mechanism of Prox1-mediated antiproliferative action was not known. Here, we provide functional evidence that Prox1 acts through a combined action in inducing the cdk inhibitor protein p27-Kip1 and suppressing Cdc25A phosphatase to block cell proliferation. Most important, by alleviating these effects of Prox1 on p27-Kip1 and Cdc25A, we were able to rescue the Prox1 antiproliferative function, indicating that these actions are of functional importance and mediate the Prox1 effect on cell cycle regulation. We propose that Prox1 is directly involved in the mechanisms that control the progression of cell cycle from G1 to S phase (Figure 10m ). In particular, we suggest that Prox1, through the regulation of p27-Kip1 and Cdc25A expression, blocks the activity of Cdk2/CyclinE complex, being thus able to inhibit the progression of cell cycle (Figure 10m) . However, based on our data we cannot exclude additional actions of these cell cycle regulators in relation to Prox1 effect. In addition, Prox1 appears to control the expression of these regulators at the transcriptional level, possibly through direct binding at their promoters. However, based on our observations we cannot totally rule out the possibility of an indirect mode of regulation and thus the detailed molecular mechanism is currently under investigation. In striking accordance, Drosophila neuroblasts lacking Prospero, the Drosophila homolog of Prox1, form tumors in both the embryonic nervous system and larval brain, 21, [33] [34] [35] being thus considered a tumor suppressor gene. Prospero suppresses the genetic program for self-renewal and cell cycle progression of Drosophila neuroblasts by affecting the expression of String (Cdc25A in mammals), Dacapo (p27-Kip1 in mammals), CycA, CycE, Encore, Rbf (retinoblastoma-family protein in mammals) and E2F genes. 21, 22, [36] [37] [38] Interestingly, similar to our data it was recently shown that Prospero inhibits cell cycle progression of neuronal progenitors in Drosophila by activating the expression of Dacapo. 36 These observations suggest a conserved mechanism for Prox1-mediated suppression of cell cycle progression from flies to mammals.
Although these studies indicate a tumor suppressor function of Prox1, recent reports suggest its involvement in tumor progression and enhancement of proliferation in other cell types and tissues. Thus, it appears that Prox1 positively regulates the cell cycle in lymphatic endothelial cells, fetal hepatic stem/progenitor cells and promotes dysplasia in colonic adenomas and colorectal cancer progression. 17, 20, 39, 40 These data underscore the complexity of Prox1 actions in cancer pathogenesis and cell cycle regulation. In all these cases, Prox1 is able to induce the expression of CyclinE1, and especially for lymphatic endothelial cells it was shown that Prox1 exerts a direct effect on activating the CyclinE1 promoter. 20 Consistently, despite the strong antiproliferative effect of Prox1 in neuroblastoma cells, it is also sufficient to induce CyclinE1 mRNA expression and promoter activation similar to lymphatic endothelial cells. However, in N2A, Prox1 exerts additional actions by activating p27-Kip1 and suppressing Cdc25A expression that manage to counteract CyclinE's effect on proliferation and further block cell cycle progression. This scenario is supported by data suggesting that p27-Kip1 and Cdc25A regulate cell cycle through their ability to inactivate or activate, respectively, the Cdk2/CyclinE complex that in its active form promotes progression of the cell cycle from G1 to S phase (Figure 10m) . Moreover, we suggest that the ability of Prox1 to induce CyclinE1 may account for the context-dependent oncogenic function of Prox1. According to our model, in these cells the Prox1-mediated induction of CyclinE1 can override its effect on p27-Kip1 and Cdc25A, or alternatively Prox1 may not be sufficient to affect their expression and hence the CyclinE's effect on proliferation prevails. Again in striking agreement, Prospero in glial precursors of Drosophila is required to maintain the mitotic potential of glia by positively regulating CyclinE expression and antagonizing the p27-Kip1 homolog, Dacapo, 41 in contrast to embryonic neuroblasts, where it suppresses CyclinE expression and induces Dacapo. Thus, in Drosophila similar to mammalian cells, Prospero affects cell cycle genes and can either promote or inhibit them depending on the cellular or developmental context.
A key question arising from our observations is whether the ability of Prox1 to block neuroblatoma cell proliferation can be utilized in therapeutic strategies. Accordingly, it was recently shown that Prox1 mediates the antiproliferative action of Interferon-g in esophageal cancer cells. 31 Interestingly, Interferong reduces proliferation and delay tumorigenicity in human neuroblastoma cells. 42, 43 Therefore, Prox1 is a candidate factor that could mediate this effect in neuroblastoma cells. Moreover, Prox1 expression is negatively regulated by miRNA-181 in human endothelial cells by direct binding to its 3 0 -untranslated mRNA. 44 Strikingly, miRNA-181 appeared to be overexpressed and strongly associated with unfavorable human neuroblastoma, considered to be an oncogenic miRNA. 45, 46 The ability of miRNA-181 to suppress Prox1 may also mediate its oncogenic function in neuroblastoma. These observations indicate that cytokines, drugs and/or miRNA-/ siRNA-based approaches could be utilized to de-repress Prox1 expression in neuroblastoma cells to promote cell cycle arrest and contribute to therapeutic approaches. Towards these aims, we are currently focussing on identifying drugs and/or pathways that can enhance Prox1 expression in neuroblastomas using highthroughput approaches.
MATERIALS AND METHODS
Cell culture, allotransplantations, transfections, viral infections, luciferase assays, chromatin immunoprecipitation assays, Fluorescence-activated cell sorting analyses and reagents Neuroblastoma cell lines were cultured and transfected as previously described. 5, [47] [48] [49] Allotransplantations, plasmids, viral infections, luciferase assays, chromatin immunoprecipitation assays, fluorescence-activated cell sorting (FACS) analysis, reagents and stable cell lines construction are described in Supplementary Materials and Methods. All animals were handled in strict accordance with good animal practice as defined by the relevant European and Greek animal welfare bodies.
Immunohistochemistry and western blot analysis Prox1 was detected using a rabbit polyclonal (ReliaTech, Wolfenbö ttel, Germany), mouse monoclonal (Millipore, Bedford, MA, USA) or an anti-FLAG antibody from Sigma (St Louis, MO, USA). 5 Anti-BrdU was detected using a mouse monoclonal (Dako, Glostrup, Denmark) or a rat antibody (Abcam, Cambridge, UK). Anti-GFP from Sigma; PCNA from DAKO; anti-pH3 from Abcam; anti-p27-Kip1 from BD Biosciences (San Jose, CA, USA); antiNotch1, -p53, -p21-Cip1, -CyclinA, -CyclinD1, -CyclinE1 and -Cdc25A from Santa Cruz (Santa Cruz, CA, USA); all antibodies were detected as previously described. 5 Immunofluorescent specimens were viewed and analyzed with a Leica (Wetzlar, Germany) confocal microscope. Statistical analysis was performed with the two-tailed paired Student's t-test. Quantification of the digital images obtained was performed using ImageJ software (NIH, Bethesda, MD, USA).
Proliferation, growth and apoptosis assays Proliferation and apoptotis assays were performed as previously described 5, [47] [48] [49] [50] and Supplementary Materials and Methods.
RNA extraction and real-time RT-PCR analysis
Total RNA was isolated by TRIZOL reagent (Ambion) followed by treatment with RQ1 DNase (Promega). Quantitative RT-PCR analysis was performed as described. 5 Primer sets are listed in Supplementary Materials and Methods.
